QBIO OTCMarkets

Q BioMed

Accelerating Biomedical Technologies from **Incubation** to **Monetization**

Q BioMed Inc. (QBIO) is a biomedical acceleration and development company focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Q BioMed Unlocks Undiscovered Biomedical Value

- Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points
- Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management
- Licenses or acquires the assets and works together to create valuation growth

QBIO INVESTORS BENEFIT FROM VALUE-CREATING INFLECTION POINTS AS ASSETS ACCELERATE THROUGH MILESTONES

SELECT FINANCIALS

Fiscal Year End	Nov 30
Market Cap (4/19/18)	~$55 M
Current Price (4/18/18)	$3.45
Avg. Volume	101,936 K
Shares Out	14M
Float	8.0 M
Inside Ownership	35%

How Q BioMed Accelerates Biomedical Technology Development

- Unlocks capital in US public markets to fund the development of assets
- Makes liquid investments in high-value assets that can produce exponential returns
- Diversifies risk over several therapies in various stages of development and deploys performance-based capital only
- Accelerates its asset's development with management and advisory teams' expertise, experience, and industry relationships

A Growing Pipeline and Strategy Mitigates Risk & Drive Shareholder Value



We are initiating manufacturing and await FDA approval of the Manufacturing facility. Revenue Expected Q3 2018

In years 1&2 QBIO is focused on licensing and acquiring assets, some with near term (6-12 months) revenue or value-creating opportunities

In YEARS 2&3 QBIO will look to grow the pipeline and monetize investments through partnerships, JV, IPO and sales revenue growth

Timeline and Milestones

Our Current Biotechnology Portfolio

Strontium Chloride Sr89 Injection, USP

BONE METASTASES
from Prostate and Breast Cancer

- 450,000 new breast and prostate cancer diagnoses each year
- 1 in 3 people will develop bone metastases from the spread of breast and prostate cancer

Current Standards of Care

- Pain is the most common sign of bone cancer, and may become more noticeable as the tumor grows
- Bone cancer can cause debilitating pain in a bone or bone region (e.g., back, pelvis, legs, ribs, arms)
- **Treatment options** include:

  PAIN MEDICATIONS - OPIOIDS - ORTHOPEDIC PROCEDURES
- Indicated to relieve bone pain from skeletal metastases from breast and prostate cancers
- Non be used with opiate based drugs and cancer therapeutics
- Studies demonstrated a prolonged progression-free result and overall survival with acceptable toxicity

QBM-001

PEDIATRIC NON-VERBAL DISORDER

- Among the >60,000 US children who develop Autism Spectrum Disorders (ASD) every year,
- 20,000 become nonverbal and will have to rely on assisted living for the rest of their life.

Current Standards of Care

- The lifetime cost of care is estimated at $10 M/person.
- No treatment with lasting effects on how children develop
- There are NO drugs currently available to ameliorate this condition.
- Orphan drugs (less than 200k patients) average price $100,000 per year.
- This pediatric nonverbal disorder, where children lose or don't develop speech and manifest with ASD symptoms is rare and limited to approximately 20,000 children a year in the US and about the same in Europe.

MARKET POTENTIAL

United States: 20,000 patients per year @ $100,000 - $2B

Europe and ROW: 30,000 Patients per year @ 100,000 - $3B

UTTROSIDE-B

LIVER CANCER
Chemotherapy

- 700,000 patients worldwide
- Short 1-year survival rate
- Estimated 39,230 adults in the US will be diagnosed every year

Current Standards of Care

Surgery—Hepatectomy or Liver transplantation

Thermal Ablation- Radiofrequency ablation (RFA) and microwave therapy

Percutaneous ethanol injection—Alcohol iinjected directly into the liver tumor

Radiation—High-energy x-rays or other particles destroy cancer cells

Drug Treatment - Tryosine kinase inhibitor antineoplastic agent, Nexavar™

Opportunity

- Sorafenib Tosylate (Nexavar™) is the only FDA approved drug for the treatment of liver cancer
- P Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and capcase activity (apoptosis in liver cancer)
- Uttroside B increases the cytotoxicity of a variety of liver cancer cell types up to 10x more potent than Sorafenib in pre clinical studies
- Cytotoxicity specific to cancerous liver cells
- Provisional patent filed

MAN 01

GLAUCOMA and Interocular Eye Pressure (IOP)

- 60 million patients worldwide
- 8 million with bilateral blindness
- Typically no early warning signs
- Therapy only slows progression, no cure

Current Standards of Care

Medical (Pharmaceuticals) - No new glaucoma pharmaceutical in 20 years (1996)

Laser Surgery - Requires two procedures and use of pharmaceuticals

Traditional Surgery (In-patient) - Requires two procedures and use of pharmaceuticals. Painful, costly, and invasive

First in class drug to treat Intraocular Eye Pressure (IOP)

- Only drug targeting the 'Schlemms' Canal which is responsible for 70%-90% of fluid drainage in the eye
- Testing shows excellent results normalizing IOP
- Primary Indication for adult open angle glaucoma

Additional indications may include:

Age Related Macular Degeneration (AMD)
Cystic Kidney Disease, Cardiovascular Disease.

Management

Denis D Corin, President and Director - Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental is building and restructuring businesses.

William Rosenstadt, General and Corporate Securities Counsel and Director - Mr. Rosenstadt is the founding and managing partner of international law Sanders Ortoli Vaughn-Flam Rosenstadt LLP and has been a practicing attorney since 1995. He advises entrepreneurs, public companies, and other corporate entities with respect to the execution of complex commercial, corporate, and international transactions.

David Laskow-Pooley, VP Scientific & Product Development - Mr. Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies.

Mr. Ari Jatwes is an analyst and a banker, with over twenty years of experience. He began his career in a large accounting firm, progressing to a reputable investment bank, where he gained his experience in mergers and acquisitions. Over the last decade Mr. Jatwes interest and focus has been in the biotech and pharma sector, which included trading biotech stocks from start up to late stage biotech companies, advising management and raising capital for their needs.



Dr. Rick Panicucci served as the Vice President of Pharmaceutical Development at STA Pharmaceutical Co. Ltd. (WuXi) and previously as Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015. He is responsible for providing scientific leadership in the areas of Developability, Formulation Development and manufacturing.

QBioMed
501 Madison Avenue
New York, NY 10222
+1 (888) 357-24351

Executive & Investors
Denis Corin, CEO
dcorin@qbiomed.com